Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for hidden antibodies in Kids' kidney disease

NCT ID NCT07516964

Knowledge-focused Sponsor: Meyer Children's Hospital IRCCS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is investigating whether certain autoantibodies, especially those targeting a protein called nephrin, play a role in nephrotic syndrome, a kidney condition that causes swelling and protein loss in urine. Researchers will analyze blood and kidney tissue from 50 children and adults with the disease using advanced lab techniques. The goal is to better understand the disease mechanisms and pave the way for more personalized, effective treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could lead to better diagnostic tests and more personalized treatments for children with nephrotic syndrome, reducing unnecessary steroid use.
What could go wrong
This is an observational study, not a treatment trial. It is small (50 participants) and early-stage, so findings may not apply to all patients or lead directly to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Oct 2036

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

0 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pediatric and adult patients with a diagnosis of podocytopathy * Patients with nephrotic syndrome and/or histological diagnosis of minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), collapsing glomerulopathy (CG), or diffuse mesangial sclerosis (DMS) * Both newly diagnosed (incident) patients and patients already under follow-up at participating centers * Availability of clinical data from medical records (including paper and/or electronic records, laboratory reports, and discharge summaries) * Availability of biological samples (e.g., blood and/or renal biopsy), if collected as part of routine clinical care * Signed informed consent by the patient or legal guardian (and assent when applicable) Exclusion Criteria: * Refusal or inability of the patient, parents, or legal guardian to provide informed consent * Lack of sufficient clinical data or unavailable biological samples required for the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Collapsing glomerulopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease focal segmental glomerulosclerosis idiopathic membranous glomerulonephritis lipoid nephrosis nephrotic syndrome nephrotic syndrome, type 4 sporadic idiopathic steroid-resistant nephrotic syndrome with collapsing glomerulopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Focal segmental glomerulosclerosis (FSGS) Minimal change nephrotic syndrome Nephrotic syndrome due to idiopathic membranous nephropathy Nephrotic syndrome with edema (diagnosis)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    14 sites in 5 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Azienda Ospedaliero Universitaria Careggi

    NOT_YET_RECRUITING

    Florence, Italy

  • Azienda Ospedaliero Universitaria Pisana

    NOT_YET_RECRUITING

    Pisa, Italy

  • Azienda Ospedaliero-Universitaria di Parma

    NOT_YET_RECRUITING

    Parma, Italy

  • Azienda USL - IRCCS

    NOT_YET_RECRUITING

    Reggio Emilia, Italy

  • Bellvitge University Hospital

    NOT_YET_RECRUITING

    Barcelona, Spain

  • Hospital General de México, Mexico City

    NOT_YET_RECRUITING

    Mexico City, Mexico

  • IRCCS Azienda Ospedaliero - Universitaria

    NOT_YET_RECRUITING

    Bologna, Italy

  • IRCCS Istituto Giannina Gaslini

    NOT_YET_RECRUITING

    Genova, Italy

  • Ludwig-Maximilians Universitat

    NOT_YET_RECRUITING

    München, Germany

  • Mayo Clinic

    NOT_YET_RECRUITING

    Rochester, Minnesota, 55902, United States

  • Meyer Children's Hospital IRCCS

    RECRUITING

    Florence, FIRENZE, 50139, Italy

  • Ospedale S. Giovanni di Dio

    NOT_YET_RECRUITING

    Florence, Italy

  • Ospedale Santa Maria Annunziata

    NOT_YET_RECRUITING

    Bagno a Ripoli, Firenze, Italy

  • Ospedale Santo Stefano

    NOT_YET_RECRUITING

    Prato, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.